Table 2.

MPST estimates (in years) of preclinical stages by gendera

ADSQSMOTH
Men
 IA1.822.161.251.96
 IB0.640.760.440.69
 II0.460.550.320.50
 IIIA0.460.550.320.50
 IIIB0.360.420.250.39
 IV0.740.880.510.80
 Total mean preclinical durationb4.485.323.094.84
Women
 IA2.442.151.362.31
 IB0.860.760.480.81
 II0.620.550.340.59
 IIIA0.620.550.350.59
 IIIB0.480.420.270.45
 IV0.990.880.550.94
 Total mean preclinical durationb6.015.313.355.69

Abbreviations: AD, adenocarcinoma; OTH, other non–small cell carcinoma; SM, small cell carcinoma; SQ, squamous cell carcinoma.

  • aThe MPST estimates should be interpreted as follows: the time for an adenocarcinoma cancer to progress from preclinical stage IA to preclinical stage II (or be clinically detected in stage IB) in a male is on average 2.46 (1.82 + 0.64) years, of which 1.82 years are spent in the preclinical state of stage IA and 0.64 years are spent in the preclinical state of stage IB.

  • bIf discovered clinically in stage IV.